Ginseng focus trial halted early – little to go on

NCT ID NCT07255755

Terminated Symptom relief Sponsor: University of East Anglia Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single 200 mg dose of American Ginseng (Cereboost) could improve attention and brain function in healthy young adults aged 18-40. Participants completed cognitive tests and gave blood samples over 6 hours. However, the trial was terminated early and only enrolled 27 people, so no reliable conclusions can be drawn.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: American Ginseng extract (Cereboost)
What this could lead to: If it worked, this could suggest a natural supplement for short-term attention or focus in healthy people.
What could go wrong: The trial was terminated early with only 27 participants, so results are incomplete and unreliable. Any benefits would be small and temporary, not a treatment for any condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATTENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type cognitive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATTENTION COGNITION

Contacts and locations

Locations

Quadram Insitute Clinical Research Facility

Norwich, Norfolk, NR4 7UQ, United Kingdom
University of East Anglia

Norwich, Norfolk, NR4 7UQ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.